lung-cancer

Scientists find the master switch controlling a key target for small cell lung cancer drugs

Delta-like ligand 3 (DLL3) is a protein selectively expressed on small cell lung cancer (SCLC) cells — and virtually not on normal adult tissue — making it an ideal cancer target. DLL3-targeting therapies are already showing clinical benefit, but understanding what controls DLL3 expression could…

Dan Manning

Dan Manning

— 1 min read
Share
Scientists find the master switch controlling a key target for small cell lung cancer drugs

Scientists find the master switch controlling a key target for small cell lung cancer drugs

Delta-like ligand 3 (DLL3) is a protein selectively expressed on small cell lung cancer (SCLC) cells — and virtually not on normal adult tissue — making it an ideal cancer target. DLL3-targeting therapies are already showing clinical benefit, but understanding what controls DLL3 expression could lead to even better treatments.

This study used comprehensive CRISPR screens to systematically identify what turns DLL3 on in SCLC. Both transcription factor-focused and genome-wide screens converged on POU2F1 as the top activator of DLL3 in this cancer context. Importantly, while POU2F1 is broadly expressed in many tissues, it plays a specific, critical role in SCLC by activating DLL3 and a broader set of neuroendocrine identity genes that define the tumor type.

Identifying POU2F1 as this master regulator opens paths to understanding why some SCLC tumors have low DLL3 expression (potentially resistant to DLL3-targeted therapies) and suggests strategies to enhance or restore DLL3 expression to make more tumors susceptible to these treatments.

Key Findings

  • CRISPR screens identified POU2F1 as the top transcriptional activator of DLL3 in SCLC
  • POU2F1 has an SCLC-specific role despite being broadly expressed across tissues
  • POU2F1 regulates a broader neuroendocrine gene program that defines SCLC identity
  • Both transcription-factor-focused and genome-wide screens independently identified POU2F1
  • Findings could explain variability in DLL3 expression and DLL3-targeted therapy response

Implications

DLL3-targeted therapies like rovalpituzumab tesirine and tarlatamab are clinically validated in SCLC. Understanding POU2F1 as a DLL3 regulator could help predict which patients respond to these drugs and enable strategies to enhance DLL3 expression in low-expressing tumors.

Caveats

Preprint, not peer reviewed. CRISPR screen findings in cell lines need validation in patient tumor samples and clinical correlation. Summary based on abstract only.

Source: bioRxiv — 2026-04-10

Read more